米非司酮治疗子宫肌瘤的疗效及对血清性激素的影响

发布时间：2018-05-11 16:40

本文选题：米非司酮 + 子宫肌瘤　；参考：《遵义医学院》2017年硕士论文

【摘要】：目的:观察米非司酮治疗子宫肌瘤的临床疗效,通过对血清性激素进行检测,从而了解其对卵巢功能的影响。方法:选取2015年7月至2016年7月我院妇科门诊就诊的诊断为子宫肌瘤的患者作为研究对象,共30例,给予12.5mg/d米非司酮治疗3个月,分别记录治疗前、治疗1、2、3个月后的子宫肌瘤体积大小、血清性激素水平、月经改变及不良反应。停药后的3天内检测血清抗苗勒氏管激素。经spss16.0分析数据,得出相关结论,全面评价米非司酮临床治疗效果。结果:1、使用米非司酮后子宫肌瘤体积均较治疗前减小,且治疗时间越长,体积缩小程度越大,差异有统计学意义(P0.05)。2、通过治疗前与治疗1、2、3个月后的时间组间的比较,发现T变化不大,差异无统计学意义(P㧐0.05)。3、通过治疗前与治疗1、2、3个月后的时间组间的比较,发现E2、P在时间组间有差异,E2、P水平随治疗时间下降,且下降呈线性趋势。4、通过治疗前与治疗1、2、3个月后的时间组间的比较,发现FSH、LH在时间组间有差异,FSH、LH水平随治疗时间下降,且下降呈线性趋势。5、米非司酮治疗3个月后30例患者全都出现闭经,闭经率100%。6、服用米非司酮3个月中出现不良反应总例数为4例,不良反应率为13.33%,程度轻。7、治疗3个月后30例患者的AMH水平均在所处年龄段的正常范围内。结论:1、12.5mg/d的米非司酮能缩小子宫肌瘤体积,且在3个月的治疗时间内,肌瘤体积缩小幅度与治疗时间成正比,缩瘤效果好。2、米非司酮能有效降低血清FSH、LH、P、E2激素水平,对T、AMH水平无明显影响,米非司酮对卵巢功能无影响。3、12.5mg/d米非司酮治疗子宫肌瘤3个月的不良反应发生率低,程度轻,短期使用是安全的。
[Abstract]:Aim: to observe the clinical effect of mifepristone in the treatment of uterine leiomyoma and to investigate the effect of mifepristone on ovarian function by detecting serum sex hormone. Methods: from July 2015 to July 2016, 30 patients diagnosed as uterine leiomyoma were treated with 12.5mg/d mifepristone for 3 months. The size of uterine leiomyoma, serum sex hormone level, menstrual changes and adverse reactions were measured after 1 and 3 months of treatment. Serum anti-Mullerian tube hormone was detected within 3 days after withdrawal. The results of spss16.0 analysis were used to evaluate the clinical effect of mifepristone. Results the volume of uterine myoma decreased after treatment with mifepristone, and the longer the treatment time, the greater the volume reduction. The difference was statistically significant (P 0.05). It was found that there was no significant difference in T between the two groups, and the difference was not statistically significant (P < 0.05). Through the comparison between the time groups before treatment and after 1 and 3 months of treatment, it was found that there was a significant difference in the level of E2P between the two groups and the level of E2P decreased with the time of treatment. The decrease showed a linear trend of .4.Through the comparison between the time groups before treatment and after 1 and 3 months of treatment, it was found that there was a difference in the level of FSH LH between the time groups and that the level of FSHN LH decreased with the time of treatment. After 3 months of mifepristone treatment, all 30 patients had amenorrhea, the amenorrhea rate was 100.6. the total number of adverse reactions in 3 months after taking mifepristone was 4 cases. The adverse reaction rate was 13.33 and the degree was light. After 3 months of treatment, the AMH level of 30 patients was within the normal range of their age. Conclusion Mifepristone can reduce the volume of uterine leiomyoma, and the reduction of myoma volume is in direct proportion to the treatment time in 3 months. Mifepristone can effectively reduce the level of serum FSHLHN PE2. Mifepristone had no effect on ovarian function. The adverse effects of mifepristone on uterine leiomyoma for 3 months were low and mild. It was safe to use mifepristone for 3 months.
【学位授予单位】：遵义医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.33

【相似文献】